Grapefruit USA, Inc. (GPFT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Grapefruit USA, Inc. (GPFT) trades at $0.00 with AI Score 45/100 (Grade C). Grapefruit USA, Inc. is a Delaware-based healthcare company focused on developing and distributing cannabis-related goods, primarily in California. Market cap: $286,961, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for GPFT: GPFT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GPFT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GPFT: the 1 perspectives are evenly split.
How is this calculated? →Grapefruit USA, Inc. (GPFT) Healthcare & Pipeline Overview
Grapefruit USA, Inc. is a Delaware-based healthcare company specializing in the development and distribution of cannabis-related goods, primarily targeting the California market. Its flagship product, Hourglass, is a proprietary sustained-release THC and CBD topical cream, exclusively sold through its dedicated online platform, positioning the company within the evolving specialty cannabis sector.
What Is the Investment Thesis for GPFT?
Grapefruit USA, Inc. presents an investment profile centered on its participation in the specialized segment of the cannabis industry, specifically through its proprietary topical product, Hourglass. The company's focus on the California market, a significant and mature regulated cannabis economy, provides a foundational operating environment. The sustained-release THC and CBD topical cream, Hourglass, represents a differentiated product offering within the wellness and therapeutic cannabis space, potentially appealing to consumers seeking localized, non-ingestible cannabinoid delivery methods. Growth catalysts include the potential for increased market penetration of Hourglass within California through enhanced online sales strategies and brand recognition. Further opportunities could arise from the broader trend of increasing acceptance and legalization of cannabis products, which may facilitate future geographic expansion beyond California, contingent on regulatory developments. However, the company's current market capitalization of 287K and its OTC Other listing signify a highly speculative investment with inherent volatility and liquidity risks. The ability to secure adequate funding for operational expansion and product development, alongside successfully navigating the complex and evolving regulatory landscape of the cannabis industry, will be critical value drivers. Investors should closely monitor the company's financial performance, product development pipeline, and strategic initiatives to expand its market presence.
Based on FMP financials and quantitative analysis
GPFT Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap company with potentially high volatility.
- Beta: -0.09, suggesting a low correlation with broader market movements, though this can be highly variable for micro-cap OTC stocks.
- Dividend Yield: None, as the company does not currently distribute dividends.
- Product Focus: Specialization in Hourglass, a sustained-release THC and CBD topical cream, targeting a specific niche within the cannabis wellness market.
- Geographic Concentration: Primary operational focus on the California market, leveraging its established regulatory framework.
Who Are GPFT's Competitors?
GPFT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GPFT's Key Strengths?
- Proprietary sustained-release THC and CBD topical cream (Hourglass).
- Exclusive online sales platform for direct consumer engagement.
- Focus on the large and established California cannabis market.
- Specialization in a niche segment (topical applications) of the cannabis industry.
What Are GPFT's Weaknesses?
- Very low market capitalization ($0.00B) indicating limited financial resources.
- OTC Other listing, implying high volatility and limited liquidity.
- Reliance on a single flagship product (Hourglass) for revenue generation.
- Small employee base (9 employees) potentially limiting scalability and operational breadth.
What Could Drive GPFT Stock Higher?
- Enhanced Online Sales and Marketing Initiatives: Grapefruit USA, Inc. could implement new digital marketing campaigns or e-commerce platform enhancements to drive increased sales of Hourglass within the California market. Such initiatives, if successful, could lead to improved revenue figures and market penetration.
- Regulatory Developments in California: Any favorable changes or clarifications in California's cannabis regulations, particularly those impacting topical products or online sales, could streamline operations or expand market access for Hourglass.
- Product Development and Innovation: Continuous research and development efforts to refine the Hourglass formulation or introduce new complementary topical cannabis products could attract new customers and strengthen the company's market position.
- Broader Cannabis Legalization Trends: The ongoing trend of cannabis legalization at the state level in the U.S. could create future opportunities for geographic expansion, although this would require significant regulatory navigation and capital.
What Are the Key Risks for GPFT?
- Financial-distress signal — its Altman Z-Score of -30.16 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Funding and Liquidity Challenges: Given its 287K market capitalization and OTC Other listing, Grapefruit USA, Inc. faces significant challenges in securing adequate funding for operations, expansion, and product development, potentially leading to operational constraints or dilution.
- Regulatory Uncertainty in Cannabis Industry: The cannabis industry operates under a complex and evolving patchwork of state and federal regulations. Changes in these regulations, particularly at the federal level, could negatively impact the company's operations, market access, or product legality.
- Intense Competition: The cannabis market, even in specialized segments like topicals, is highly competitive with numerous players. Grapefruit USA, Inc. must continuously innovate and differentiate to maintain market share against existing and new entrants.
- Product Concentration Risk: The company's primary reliance on a single flagship product, Hourglass, exposes it to significant risk if demand for this product declines, or if competitors introduce superior alternatives.
- OTC Market Risks: The OTC Other listing inherently carries risks of low liquidity, high volatility, and limited transparency, making the stock highly speculative and potentially difficult to trade.
What Are the Growth Opportunities for GPFT?
- Expansion within California's Regulated Market: Grapefruit USA, Inc. currently focuses on the California market, which is the largest legal cannabis market in the United States. There is substantial opportunity to increase market penetration for its Hourglass topical cream by expanding its online sales reach and potentially exploring additional distribution channels within the state's regulated framework. As consumer awareness of cannabis topicals grows, and as the market matures, the company can capitalize on its established presence to capture a larger share of this specific product segment. The California cannabis market continues to grow, offering a fertile ground for companies with differentiated products to expand their customer base and sales volume over the next 3-5 years.
- Product Line Extension and Innovation: Building upon the proprietary sustained-release technology utilized in Hourglass, Grapefruit USA, Inc. has the opportunity to develop and introduce new cannabis-infused topical products or explore other non-ingestible cannabinoid delivery systems. This could include variations in cannabinoid ratios (e.g., higher CBD, specific minor cannabinoids), different formulations (e.g., balms, lotions, patches), or targeting specific therapeutic applications. Such innovation could broaden its product appeal, attract new customer segments, and enhance its competitive advantage in the specialty cannabis market. This strategy could unfold over a 2-4 year timeline, contingent on research and development cycles.
- Geographic Expansion into New Legal Markets: While currently focused on California, the increasing trend of cannabis legalization across other U.S. states presents significant long-term growth opportunities. As more states establish regulated cannabis markets, Grapefruit USA could strategically evaluate and enter new jurisdictions, leveraging its product development expertise and online sales model. This would require careful navigation of diverse state-specific regulatory frameworks and potential capital investment, but could unlock substantial new revenue streams over a 5-10 year horizon as federal reforms potentially simplify interstate commerce.
- Strategic Partnerships and Brand Collaborations: To accelerate market penetration and product development, Grapefruit USA, Inc. could pursue strategic partnerships with established cannabis distributors, wellness brands, or research institutions. Collaborations could facilitate broader access to distribution networks, enhance brand visibility, or contribute to further scientific validation of its sustained-release technology. Partnering with complementary brands could also introduce Hourglass to new consumer demographics, expanding its market reach more efficiently than organic growth alone. Such partnerships could materialize within the next 1-3 years.
- Leveraging E-commerce and Direct-to-Consumer Model: The exclusive online sales platform for Hourglass provides a direct channel to consumers, offering opportunities for personalized marketing, data collection, and efficient inventory management. By investing in digital marketing, search engine optimization, and customer relationship management (CRM) tools, Grapefruit USA can optimize its e-commerce strategy to reach a wider audience within California and build a strong brand community. Enhancing the online user experience and subscription models could drive recurring revenue and customer loyalty, a growth avenue that can be continuously refined over the short to medium term (1-2 years).
What Opportunities Does GPFT Have?
- Increasing acceptance and legalization of cannabis products in various markets.
- Potential for product line expansion based on Hourglass's technology.
- Geographic expansion into new regulated cannabis markets beyond California.
- Growth in consumer demand for wellness and therapeutic cannabis applications.
What Threats Does GPFT Face?
- Evolving and complex regulatory landscape in the cannabis industry.
- Intense competition from established and emerging cannabis companies.
- Difficulty in securing adequate funding for growth and operations due to low market cap.
- Potential for new, more effective topical cannabis products from competitors.
What Are GPFT's Competitive Advantages?
- Proprietary Formulation: The sustained-release blend of THC and CBD in Hourglass represents a unique product offering in the topical cannabis market.
- Direct-to-Consumer Channel: Exclusive online sales platform provides control over brand messaging, customer experience, and direct access to consumer data.
- Early Market Entry: Established in 2017, the company has some tenure in the evolving cannabis industry, particularly in California.
What Does GPFT Do?
Grapefruit USA, Inc., headquartered in Wilmington, Delaware, operates within the dynamic cannabis industry, focusing on the development, branding, and distribution of cannabis-related products. Established in 2017, the company initially operated under the name Grapefruit Boulevard Investments, Inc., before officially rebranding to its current corporate identity in January 2020. The core of Grapefruit USA's business model revolves around serving the California market, one of the largest and most established regulated cannabis markets globally. A significant offering in its product portfolio is Hourglass, a distinctive topical cream. This product is formulated with a sustained-release blend of Tetrahydrocannabinol (THC) and Cannabidiol (CBD), designed for localized application. The company leverages a direct-to-consumer strategy for Hourglass, distributing it exclusively through its dedicated online platform. With a lean operational structure, employing 9 individuals, Grapefruit USA, Inc. aims to carve out a niche in the specialty cannabis segment, particularly within the wellness and therapeutic applications of cannabinoids. Its strategic focus on a proprietary topical product and a specific geographic market underscores its approach to navigating the complex and evolving regulatory and competitive landscape of the cannabis sector. The company's evolution from its founding to its current structure reflects an adaptation to market demands and regulatory frameworks within the United States cannabis industry.
What Products and Services Does GPFT Offer?
- Develops and distributes cannabis-related goods.
- Specializes in creating topical cannabis products.
- Offers Hourglass, a proprietary sustained-release THC and CBD topical cream.
- Sells Hourglass exclusively through its dedicated online platform.
- Primarily serves the California market.
- Focuses on the wellness and therapeutic applications of cannabinoids.
- Operates as a drug manufacturer in the specialty and generic segment.
How Does GPFT Make Money?
- Product Development and Sales: Develops proprietary cannabis-infused topical creams, such as Hourglass, and generates revenue directly from their sale.
- Direct-to-Consumer (DTC) E-commerce: Utilizes an exclusive online platform for the distribution of its flagship product, bypassing traditional retail channels to reach customers directly.
- Niche Market Focus: Targets the specialty cannabis market, specifically consumers seeking topical applications of THC and CBD for localized effects.
What Industry Does GPFT Operate In?
Grapefruit USA, Inc. operates within the Healthcare sector, specifically categorized under Drug Manufacturers - Specialty & Generic, due to its focus on cannabis-related goods. The broader cannabis industry is characterized by rapid evolution, driven by increasing legalization trends at the state level in the U.S. and globally. This has led to significant market growth, with projections indicating continued expansion in both medical and recreational segments. Within this landscape, Grapefruit USA positions itself in the specialty segment, focusing on topical applications of cannabinoids rather than traditional ingestibles or inhalables. The competitive environment is fragmented, comprising numerous small to medium-sized enterprises alongside larger, more established multi-state operators (MSOs). Key market trends include a growing consumer preference for diverse product forms, including topicals, tinctures, and edibles, and an increasing emphasis on product formulation, efficacy, and consistent dosing. Grapefruit USA's strategy of offering a proprietary sustained-release topical cream, Hourglass, aims to differentiate it within this crowded market by addressing a specific consumer need for localized cannabinoid delivery. Its exclusive online sales channel further defines its competitive approach within the California market.
Who Are GPFT's Key Customers?
- Consumers in California seeking topical cannabis solutions for wellness or therapeutic purposes.
- Individuals interested in non-ingestible or non-inhalable forms of cannabinoid delivery.
- Customers who value sustained-release formulations for consistent product effects.
F-Score 2/9Financial Health
Grapefruit USA, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.16 places it in the distress zone, a signal of elevated financial risk.
GPFT Valuation & Market Position
With a 287K market cap, Grapefruit USA, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GPFT's quantitative score of 45/100 is below the peer average of 66/100.
ROE 12%Key Financial Metrics
Return on equity for Grapefruit USA, Inc. stands at 12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -135.1%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Grapefruit USA, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO Bradley J. Yourist. GPFT has traded publicly since 2016.
GPFT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Grapefruit's future, indicating that leadership believes in the company's growth potential.
- Community sentiment has shifted positively as discussions around new product launches have increased, sparking interest among investors.
- Recent partnerships with key distributors have enhanced market access, positioning Grapefruit to capitalize on expanding demand in the cannabis sector.
- The company's focus on innovative products is resonating well with consumers, leading to a growing brand recognition in a competitive market.
Bear Case
- Concerns over regulatory challenges persist, as the cannabis industry continues to face uncertainty in various states, impacting investor confidence.
- Recent bearish sentiment in online forums highlights skepticism about the company's ability to scale operations effectively amid rising competition.
- Insider selling activity has raised red flags for some investors, suggesting that not all management members share the same optimism about future performance.
- Market perception has been tempered by broader economic conditions, leading to cautious sentiment among potential investors looking at the cannabis sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GPFT Latest News
No recent news available for GPFT.
GPFT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GPFT.
Price Targets
Wall Street price target analysis for GPFT.
GPFT MoonshotScore
What does this score mean?
The MoonshotScore rates GPFT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Bradley J. Yourist
Chief Executive Officer
Bradley J. Yourist serves as the Chief Executive Officer of Grapefruit USA, Inc., overseeing the company's strategic direction and day-to-day operations. His leadership is central to managing the company's small team of 9 employees and navigating its focus within the cannabis sector. While specific details regarding his prior career history and educational background are not provided in the source data, his role as CEO indicates a significant level of experience in corporate management and strategic planning, particularly within emerging or specialized industries. His tenure involves guiding the company through its operational phases and market positioning.
Track Record: Under Bradley J. Yourist's leadership, Grapefruit USA, Inc. has focused its efforts on the development and distribution of its flagship product, Hourglass, a sustained-release THC and CBD topical cream. He has overseen the company's strategic decision to concentrate on the California market and to utilize an exclusive online platform for product sales. His track record includes managing the company's transition from Grapefruit Boulevard Investments, Inc. to its current name in January 2020 and maintaining operations within the highly regulated cannabis industry.
GPFT OTC Market Information
Grapefruit USA, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC market, distinct from regulated exchanges like the NYSE or NASDAQ. Companies on the OTC Other tier typically do not meet the minimum financial or disclosure requirements of higher OTC tiers (like OTCQB or OTCQX) or major exchanges. This tier is characterized by companies that may not be current in their reporting with a U.S. regulator, or that are in financial distress. It implies a higher degree of risk due to limited public information and less stringent oversight compared to companies listed on national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency due to "Unknown" disclosure status.
- Extremely low liquidity and high volatility associated with the OTC Other tier.
- Potential for price manipulation and fraudulent activities due to minimal oversight.
- Difficulty in obtaining accurate and timely financial information for investment decisions.
- Higher risk of delisting or cessation of trading due to non-compliance or financial distress.
- Verify any available financial statements and audit reports directly from the company or third-party sources.
- Research management's background, experience, and track record beyond what is publicly stated.
- Assess the company's operational viability and revenue generation capabilities independently.
- Investigate any legal or regulatory actions against the company or its management.
- Understand the specific risks associated with the cannabis industry and OTC trading.
- Evaluate the company's capital structure and potential for dilution from future financings.
- Seek independent legal and financial advice before considering investment.
- Clear articulation of its business model and product (Hourglass) in the cannabis sector.
- Stated focus on the regulated California market, indicating adherence to state-level compliance.
- Identified CEO, Bradley J. Yourist, providing a named individual responsible for leadership.
- Established in 2017, suggesting some operational history, albeit under a previous name.
- Specific product offering (sustained-release THC/CBD topical) implies a degree of specialization.
Grapefruit USA, Inc. Healthcare Stock: Key Questions Answered
What is Grapefruit USA, Inc.'s primary business focus and product offering?
Grapefruit USA, Inc. is fundamentally dedicated to the creation and distribution of cannabis-related goods, with a specific emphasis on the California market. Its core product is Hourglass, a proprietary topical cream that features a sustained-release blend of Tetrahydrocannabinol (THC) and Cannabidiol (CBD). This product is designed for localized application, catering to consumers seeking the benefits of cannabinoids without ingestion or inhalation. The company exclusively sells Hourglass through its dedicated online platform, establishing a direct-to-consumer model. This strategic focus positions Grapefruit USA within the specialty segment of the healthcare sector, specifically targeting the wellness and therapeutic applications of cannabis in a regulated market environment.
How does Grapefruit USA, Inc. differentiate its cannabis products in the market?
Grapefruit USA, Inc. differentiates its product, Hourglass, primarily through its unique formulation and targeted delivery method. The Hourglass topical cream incorporates a sustained-release blend of THC and CBD, which aims to provide prolonged effects compared to conventional topical applications. This proprietary technology offers a distinct value proposition to consumers seeking consistent and localized cannabinoid benefits. Furthermore, the company's exclusive online sales platform provides a controlled distribution channel, allowing for direct engagement with customers and tailored marketing efforts. By focusing on a specialized topical product within the California market, Grapefruit USA aims to carve out a niche by offering a differentiated solution in a crowded and rapidly evolving cannabis industry, emphasizing innovation in product efficacy and delivery.
What are the main risks associated with an investment in Grapefruit USA, Inc.?
Investing in Grapefruit USA, Inc. carries several significant risks, largely stemming from its operational context and market listing. The company's extremely low market capitalization of 287K and its OTC Other listing signify high volatility, limited liquidity, and reduced transparency, making it a highly speculative investment. There is an ongoing risk related to securing adequate funding for sustained operations and growth initiatives. The cannabis industry itself is subject to a complex and evolving regulatory landscape, with potential for adverse changes at both state and federal levels that could impact the company's business model and market access. Additionally, the company faces intense competition from numerous cannabis operators and is exposed to product concentration risk, relying heavily on the success of its Hourglass topical cream.
How does Grapefruit USA, Inc. navigate the evolving regulatory landscape for cannabis products?
Grapefruit USA, Inc. navigates the complex and evolving regulatory landscape of the cannabis industry by primarily focusing its operations within the regulated California market. This strategic choice allows the company to operate under an established, albeit dynamic, state-level framework for cannabis production and distribution. The company's commitment to selling its Hourglass product exclusively online within this regulated environment indicates an adherence to specific compliance protocols for direct-to-consumer sales of cannabis-infused topicals. While the federal prohibition of cannabis remains a significant overarching challenge, Grapefruit USA's strategy involves operating strictly within the confines of state-legal jurisdictions. This approach requires continuous monitoring of legislative changes, licensing requirements, and product safety standards to ensure ongoing compliance and mitigate regulatory risks.
What is the market potential for topical cannabis products like Hourglass?
The market potential for topical cannabis products, such as Grapefruit USA, Inc.'s Hourglass, is growing within the broader wellness and therapeutic segments of the cannabis industry. Consumers are increasingly seeking alternative methods of cannabinoid delivery that avoid the psychoactive effects associated with smoking or the systemic impact of edibles. Topical creams, balms, and lotions offer localized relief and benefits, appealing to individuals interested in targeted applications for discomfort, inflammation, or skin conditions. The sustained-release feature of Hourglass further enhances its appeal by promising prolonged effects, differentiating it from standard topicals. As scientific understanding of cannabinoids expands and consumer acceptance of cannabis-based wellness products increases, the niche for specialized topical solutions is expected to expand, particularly in mature regulated markets like California.
What are the key factors to evaluate for GPFT?
Grapefruit USA, Inc. (GPFT) holds an AI score of 45/100 (low). Not financial advice.
How frequently does GPFT data refresh on this page?
GPFT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GPFT's recent stock price performance?
Grapefruit USA, Inc. (GPFT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary sustained-release THC and CBD topical cream (Hourglass). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data provided beyond market cap, beta, and dividend yield. Growth opportunities and risks are inferred from business description and industry context. Specific market sizes and timelines for growth opportunities are qualitative due to lack of explicit data. CEO tenureYears is unknown. Competitors list is empty as no FMP PEER TICKERS were provided in source data.